Navigation Links
GlaxoSmithKline Recognizes University of Michigan's Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
Date:8/19/2007

New Award and Fellowship Supported by Multi-Year $1.3 Million Grant to the

ASCO Foundation

PHILADELPHIA, Aug. 16 /PRNewswire/ -- Daniel F. Hayes, MD, a University of Michigan oncologist and cancer researcher whose work in clinical and laboratory studies has advanced the management of breast cancer worldwide, was named today as the first winner of the annual Gianni Bonadonna Breast Cancer Award. Supported by a multi-year grant of more than $1.3 million from GlaxoSmithKline Oncology (GSK), the award will be presented by the American Society of Clinical Oncology (ASCO) and The ASCO Foundation at the Breast Cancer Symposium in San Francisco on September 7, 2007.

"GSK is honored to sponsor this award which is being presented to Dr. Daniel Hayes, a dedicated researcher who has been at the forefront of individualized breast cancer therapy," said Paolo Paoletti, MD, Senior Vice President of the Oncology Medicine Development Center at GlaxoSmithKline. "His contributions to the field of oncology have had an important impact on our knowledge about monitoring and managing the disease, and his findings have translated into real-world benefits for patients."

Dr. Hayes, who is Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, is a widely recognized expert in breast cancer clinical research, particularly with new hormonal and chemotherapeutic treatments. He and his colleagues published the first reports on the CA15-3 blood test, currently used worldwide to evaluate breast cancer patients. Dr. Hayes' more recent research focuses on pharmacogenomics, and understanding the key role genes play in chemotherapy treatment.

The new award and an accompanying fellowship were created in honor of one of the giants of modern-day medical oncology, Dr. Gianni Bonadonna, of the Instituto Nazionale Tumori in Milan, Italy. Dr. Bonadonna was responsible for ground-breaking research i
'/>"/>

SOURCE GlaxoSmithKline

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. Fermentation Cell Culture: University Style
3. Fueling our economy with the University of Wisconsin
4. CIO Leadership Series: Ed Meachen, University of Wisconsin System
5. University, business leaders convene in Wausau
6. University of South Florida expands GE Healthcare relationship
7. State and university form network for entrepreneurial outreach
8. University center offers speed boost to manufacturers
9. Building the modern public-purpose university should be UW Systems goal
10. University Research Park to add 20 incubator suites
11. University Research Park forms ties with German tech center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
(Date:8/26/2015)... BEIJING , August 26, 2015 Israel ... DiaCardio wins 1 st place  Wayerz comes ... in Israel by venture capital fund JVP, ... including the US, China , Israel ... America .  Impressive achievement for the Israeli representatives ...
(Date:8/26/2015)... 26, 2015 After litigating and negotiating ... relating to P2i United States patent ... in the United States without any ... of either party. As a result of the parties, settlement, ... California dismissed the case without prejudice. ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial ... with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to ... regulatory pathways., , Stem Cell Meeting on the Mesa ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... In an address to,shareholders at the company,s ... ) Chairman and CEO David B. Snow Jr. ... designed to deliver strong,continuing earnings growth through 2008 ... specialty pharmacy to retaining and winning,customers, and advanced ...
... May 22 /PRNewswire-FirstCall/ - In accordance with the,terms ... Inc.,"Atrium" (TSX: ATB) today announced that it has ... Chemicals division for total proceeds of,US$166.4 million in ... is now a health and nutrition pure-play and ...
... CT Injection System Technology Detects Extravasations during CT ... ... MEDRAD, INC., announced today,that its XDS(TM) Extravasation Detector has ... a technology that aids in the,detection of leaking intravenous contrast ...
Cached Biology Technology:Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 2Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 3Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 4MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 2MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 3
(Date:8/24/2015)... 2015 The consulting company Frost & ... manufacturer DERMALOG and its customized solutions and products for ... of the Year Award". DERMALOG is particularly successful with a ... -Cross reference: Picture is available at AP Images ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... fond of talking about it as are politicians, economists ... The problem is that the term sustainability can refer ... at the Technische Universitaet Muenchen have shed light on ... science they have managed to give the term "sustainability" ...
... School of Medicine found that women may have a slightly higher ... acute coronary syndrome (ACS), but that these differences appear to be ... study, published in the August 26, 2009 issue of the ... however that overall there was no significant difference in mortality observed ...
... use wireless sensors, which can monitor chemical processes or ... wireless network. Still, many facilities that could benefit ... use a wired network instead, because the reliability, speed ... do not meet their needs. The U.S. ...
Cached Biology News:New tools for sustainable farming 2New tools for sustainable farming 3Study finds women slightly more likely to die than men in the 30 days following a heart attack 2SRNL, automakers to develop high-performance wireless sensors networks 2SRNL, automakers to develop high-performance wireless sensors networks 3
...
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
... degradation of single-stranded DNA and RNA endonucleolytically ... nuclease prefers ssDNA over dsDNA by 30,000-fold, ... double-stranded DNA from both ends (1,2). Mung ... mapping studies (3,4), for flushing staggered ends ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: